Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2015.3790 mmr-12-03-3439 Articles Integrative meta-analysis of differentially expressed genes in osteoarthritis using microarray technology WANGXI NINGYUJIE GUOXIONG School of Public Health, Xi'an Jiaotong University Health Science Center, Key Laboratory of Trace Elements and Endemic Diseases, National Health and Family Planning Commission, Xi'an, Shaanxi 710061, P.R. China Correspondence to: Professor Xiong Guo, School of Public Health, Xi'an Jiaotong University Health Science Center, Key Laboratory of Trace Elements and Endemic Diseases, National Health and Family Planning Commission, 76 Yanta West Road, Xi'an, Shaanxi 710061, P.R. China, E-mail: guox@mail.xjtu.edu.cn 9 2015 15 05 2015 12 3 3439 3445 17 08 2014 22 04 2015 Copyright © 2015, Spandidos Publications 2015 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

The aim of the present study was to identify differentially expressed (DE) genes in patients with osteoarthritis (OA), and biological processes associated with changes in gene expression that occur in this disease. Using the INMEX (integrative meta-analysis of expression data) software tool, a meta-analysis of publicly available microarray Gene Expression Omnibus (GEO) datasets of OA was performed. Gene ontology (GO) enrichment analysis was performed in order to detect enriched functional attributes based on gene-associated GO terms. Three GEO datasets, containing 137 patients with OA and 52 healthy controls, were included in the meta-analysis. The analysis identified 85 genes that were consistently differentially expressed in OA (30 genes were upregulated and 55 genes were downregulated). The upregulated gene with the lowest P-value (P=5.36E-07) was S-phase kinase-associated protein 2, E3 ubiquitin protein ligase (SKP2). The downregulated gene with the lowest P-value (P=4.42E-09) was Proline rich 5 like (PRR5L). Among the 210 GO terms that were associated with the set of DE genes, the most significant two enrichments were observed in the GO categories of 'Immune response', with a P-value of 0.000129438, and 'Immune effectors process', with a P-value of 0.000288619. The current meta-analysis identified genes that were consistently DE in OA, in addition to biological pathways associated with changes in gene expression that occur during OA, which may provide insight into the molecular mechanisms underlying the pathogenesis of this disease.

 osteoarthritis meta-analysis differentially expressed genes Introduction

Osteoarthritis (OA) is the most prevalent joint disease and is characterized by an abnormal remodeling of joint tissues, which is predominantly driven by inflammatory mediators within the affected joint (1,2). The pathological changes of OA primarily take place in the articular cartilage, and include cartilage degeneration, matrix degradation and synovial inflammation (3–5). Clinically, features of OA include pain, stiffness, limitation of motion, swelling and deformity (6). Synovial inflammation is hypothesized to be the primary underlying etiology in OA (3). However, the biological mechanisms associated with OA remain to be elucidated.

Microarray, a high-throughput genomics technology, has been developed in order to improve the understanding of complex interactions and networks in disease development (7). Thousands of genes on a genome-wide scale have been measured using microarray technology (8). The successful identification of gene expression signatures that may provide insights into OA pathogenesis and differentiate the diseased state from a healthy state, requires an adequate sample size and heterogeneous datasets (9). Although numerous microarray studies have generated lists of differentially expressed (DE) genes, there are inconsistencies among the results of such studies, due to the limitation of the small sample sizes involved (10).

To overcome these difficulties, meta-analysis has previously been applied to publicly-available genome-wide expression datasets from studies on a number of diseases (11–13). The use of meta-analysis may improve reliability and generalizability, and permit a more precise estimation of gene expression (11). Meta-analyses provide enhanced statistical power, thereby obtaining more robust and reliable gene signatures (7,14–17). Recently, integrative meta-analysis of expression data (INMEX), a new user-friendly microarray meta-analysis tool, has been developed to support meta-analysis of multiple gene expression datasets (18).

In order to overcome the limitations of individual studies, resolve inconsistencies in results, and reduce false-positive or false-negative associations due to random errors, a microarray meta-analysis was performed in the present study. The objective was to identify differentially expressed (DE) genes and biological processes associated with gene expression signature in OA.

 Materials and methods Identification of eligible gene expression datasets of OA

A search of microarray datasets was performed that examined DE genes between OA and healthy controls. The NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) (19) was used to identify suitable microarray datasets. The keyword 'osteoarthritis' was used for this search. Studies were included in the analysis if they: Were based on gene expression profiling of blood or synovial membrane samples; contained sufficient data to perform a meta-analysis; and included patients diagnosed with OA, based on OA classification criteria (20). The following information was extracted from each of the studies that were selected: GEO accession; sample type; platform; numbers of patients and healthy controls; and gene expression data.

 Meta-analysis of microarray datasets

All available OA microarray datasets that met the inclusion criteria were downloaded from the NCBI GEO database. Data tables containing gene expression or relative gene expression values were constructed, with genes/probes in the rows, and samples in the columns. The datasets were uploaded to INMEX (http://www.inmex.ca/INMEX) (18), and the data was subsequently annotated by converting different gene or probe ID to Entrez IDs. For each probe-set, intensity values were log-transformed and/or normalized to zero mean and unit variance, which is the normalization method for high density oligonucleotide array data, as reported by Bolstad et al (21). When all datasets had been uploaded, processed and annotated, a data integrity check was performed prior to the meta-analysis stage.

The random effects model presumes that different studies present substantial diversity, and evaluates between study variance as well as within study sampling error (22,23). The random effects model is used when the between-study heterogeneity is significant (23). The INMEX program was used to conduct statistical analysis (18).

 Functional analysis

The functional analysis of INMEX generates new hypotheses by exploiting characteristics of the DE gene lists identified in meta-analysis. A heat map created by 'Pattern extractor' produced gene expression profiles across different datasets/conditions.

In order to examine the functions of the genes in the gene list, gene ontology (GO) enrichment analysis was performed, which detected enriched functional attributes based on gene-associated GO terms, using the hypergeometric test (http://www.geneontology.org/) (24). Functional analysis was performed using the INMEX program (18).

 Results Studies included in the meta-analysis

Three GEO data sets, which met the inclusion criteria, were identified (Table I) (4,25,26). These datasets consisted of two synovial membrane datasets and one blood dataset, and included a total of 137 patients with OA and 52 controls. Selected details of the individual studies are summarized in Table I.

 Meta-analysis of gene expression in OA

A random effects model of effect size (ES) measures was used to integrate gene expression patterns. The present study incorporated between-study heterogeneities across studies, because the estimated Q-value was not in an approximately chi-squared distribution. DE genes with P<0.05 were selected. In the current analysis, 1 'gained' gene and 13402 'lost' genes were identified (Fig. 1). Gained genes are DE genes that were only identified in the meta-analysis (26). The single gained gene exhibited relatively weak but consistent expression profiles across the three different datasets. The large sample size obtained by consisting of the datasets made it possible declare this a DE gene with increased certainty. Lost genes are genes which were identified as DE genes in any of the individual analyses, but not in the meta-analysis. These genes also presented conflicting changes in expression profiles, or large variations across the different studies.

 Identification of differentially expressed genes in OA

A total of 85 genes were identified, which were consistently differentially expressed in OA. Among these 85 DE genes, 30 were upregulated and 55 were downregulated. A list of the top 20 upregulated and downregulated genes is shown in Table II The upregulated gene with the lowest P-value (P=5.36E-07) was S-phase kinase-associated protein 2, E3 ubiquitin protein ligase (SKP2). The downregulated gene with the lowest P-value (P=4.42E-09) was Proline rich 5 like (PRR5L).

 Identification of differentially expressed genes in the synovial membrane of patients with OA

An additional meta-analysis was performed on the results from the 2 synovial membrane samples, following exclusion of the third study, which used peripheral blood. A list of the top 20 upregulated and downregulated genes is shown in Table III. The upregulated genes with the lowest P-values (both P=0.004003) were JAZF zinc finger 1 (JAZF1) and Guanine nucleotide binding protein (G-protein), β polypeptide 4 (GNB4), which are involved in coupling membrane receptors to effector proteins, such as ion channels and enzymes (27). The downregulated gene with the largest ES (ES=2.0472; P=0.004003) was multiple inositol-polyphosphate phosphatase 1 (MINPP1). A number of the downregulated genes were related to inflammatory factors (Table III).

 Functional analysis

GO analysis of the DE genes was performed in order to identify the biological processes associated with changes in gene expression in OA. The analysis identified 210 significant enrichments of the DE genes, which were categorized to 10 GO terms (Fig. 2). The two enrichments with the lowest P-values were in the GO category of 'Immune response', with a P-value of 0.000129438, and 'Immune effector process', with a P-value of 0.000288619. Other significant GO categories included 'Regulation of humoral immune response' (P=0.000308832), 'Regulation of immune response' (P=0.00055514) and 'Positive regulation of immune system process' (P=0.00059351; Table IV).

 Discussion

A number of genes are differentially expressed genes between patients with OA and healthy controls, and it is necessary to identify the genes that may enhance understanding of the molecular and cellular processes, which are involved in the pathogenesis of OA. Although a large quantity of data may be produced using microarray studies, the small sample size of these studies is a significant obstacle to the identification of DE genes. A meta-analysis of multiple microarray datasets increases the sample size, rendering the identification of DE genes more reliable.

In the present study, a meta-analysis was performed using three publicly available GEO datasets in order to identify common biological mechanisms involved in the pathogenesis of OA. The analysis identified 85 genes that were consistently differentially expressed in OA (30 upregulated and 55 downregulated). The upregulated gene with the largest ES was SKP2, which is known to be involved in the inhibition of cell growth and the promotion of apoptosis. Kitagawa concluded that SKP2 controls the p300–p53 signaling pathway in cancer cells (28). Furthermore, this gene encodes a member of the F-box protein family, which is characterized by a ~40 amino acid motif, the F-box (29). The downregulated gene with the lowest P-value was PRR5L, which suppresses mTOR complex 2 (mTORC2)-mediated hydrophobic motif phosphorylation of protein kinase C, but not that of protein kinase B (30). In addition, the PRR5L protein may function to modulate the activity of mTORC2 in a substrate-dependent manner (30). Actinin α 1 (ACTN1), an upregulated gene, encodes an actin-binding protein, which exerts multiple effects in a variety of cell types. ACTN1 may protect osteoclasts from tumor necrosis factor-α (TNF-α); induce apoptosis through increasing the expression of the anti-apoptotic protein, Bcl-2; activate survival signals; and promote Akt phosphorylation and NF-κB activation (31). Although it is currently unclear exactly how these genes contribute to OA, they may be useful as potential biomarkers to facilitate early diagnosis or to monitor the efficacy of treatment in this disease. A number of these genes provide insights into the molecular mechanisms underlying the pathophysiology of OA.

Although osteoarthritis (OA) is understood to be a degradative articular cartilage disease, there is increasing data demonstrating the involvement of the immune system. In recent epidemiological studies involving a large number of patients with OA, an inflammatory synovium has been shown to be involved in increased damage to the cartilage (32) and pain (33). Immune cells, such as T cells, B cells and macrophages, have been identified in the synovial tissue of patients with OA (34–36). Furthermore, immunoglobulins and immune complexes against cartilage components have been detected in the plasma, synovium and cartilage of patients with OA (37), and it has been shown that the synovium is involved in complement activation in OA (38). In the present study, 210 significantly enriched GO terms associated with the DE genes were identified using a meta-analysis. The three enriched terms with the lowest P-values were 'Immune response', 'Immune effector process' and 'Regulation of humoral immune response', which were all involved in the immune system. The identified GO terms may be grouped into a smaller number of categories: 'Response to stimulus', 'Signal transduction', 'Regulation of response to stimulus', 'Immune system process', 'Immune response', 'Regulation of apoptotic process', 'Regulation of programmed cell death', 'Regulation of cell death', 'Apoptotic process' and others. Although it is difficult to identify all the significant functional categories that are expressed differentially in OA, the GO categories identified here, merit further investigation in subsequent studies.

There were certain limitations to the present study, which ought to be considered. Firstly, heterogeneity and confounding factors may have distorted the analysis. Clinical samples may have been heterogeneous with respect to clinical activity, severity or gender. Secondly, there are differences in gene expression between tissues, such as blood and synovial membrane, that were not considered. Although an additional subgroup analysis of the synovial membrane samples was performed, this only included two studies. By contrast, the initial meta-analysis integrated the results obtained from different tissues, which should have enabled detection of the genes that may have been missed in an analysis of two studies only.

In conclusion, the meta-analysis of microarray studies that was performed in the present study, provided an overview of differential gene expression in OA; identifying 85 differential expressed genes (30 upregulated and 55 downregulated genes). Future studies to validate these genes as markers for the diagnosis and response to biological therapy for OA may provide further insight into their involvement in the development and progression of OA.

 Acknowledgments

This study was supported by the Key Scientific and Technological Innovation Special Projects of Shaanxi '13115' of China (grant no. 2009ZDKG-79) and the National Natural Science Foundation of China (grant no. 81472924).

 References AignerTRoseJMartinJBuckwalterJAging theories of primary osteoarthritis: From epidemiology to molecular biologyRejuvenation Res7134145200410.1089/154916804155296415312300 LoeserRFGoldringSRScanzelloCRGoldringMBOsteoarthritis: A disease of the joint as an organArthritis Rheum6416971707201210.1002/art.34453223925333366018 BenitoMJVealeDJFitzGeraldOvan den BergWBBresnihanBSynovial tissue inflammation in early and late osteoarthritisAnn Rheum Dis6412631267200510.1136/ard.2004.025270157312921755629 MaCHLvQCaoYGenes relevant with osteoarthritis by comparison gene expression profiles of synovial membrane of osteoarthritis patients at different stagesEur Rev Med Pharmacol Sci18431439201424563447 DuanCGuoXZhangXDComparative analysis of gene expression profiles between primary knee osteoarthritis and an osteoarthritis endemic to Northwestern China, Kashin-Beck diseaseArthritis Rheum62771780201010.1002/art.2728220131229 SellamJBerenbaumFThe role of synovitis in pathophysiology and clinical symptoms of osteoarthritisNat Rev Rheumatol6625635201010.1038/nrrheum.2010.15920924410 ChoiSJRhoYHJiJDSongGGLeeYHGenome scan meta-analysis of rheumatoid arthritisRheumatology (Oxford)45166170200610.1093/rheumatology/kei128 GolubTRSlonimDKTamayoPMolecular classification of cancer: Class discovery and class prediction by gene expression monitoringScience286531537199910.1126/science.286.5439.53110521349 RamasamyAMondryAHolmesCCAltmanDGKey issues in conducting a meta-analysis of gene expression microarray datasetsPLoS Med5e184200810.1371/journal.pmed.0050184187679022528050 SiddiquiASDelaneyADSchnerchAGriffithOLJonesSJMarraMASequence biases in large scale gene expression profiling dataNucleic Acids Res34e83200610.1093/nar/gkl404168405271524917 GriffithOLMelckAJonesSJWisemanSMMeta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkersJ Clin Oncol2450435051200610.1200/JCO.2006.06.733017075124 RungJBrazmaAReuse of public genome-wide gene expression dataNat Rev Genet148999201310.1038/nrg3394 CahanPRovegnoFMooneyDNewmanJCSt LaurentGIIIMcCaffreyTAMeta-analysis of microarray results: Challenges, opportunities, and recommendations for standardizationGene4011218200710.1016/j.gene.2007.06.016176519212111172 LeeYHNathSKSystemic lupus erythematosus susceptibility loci defined by genome scan meta-analysisHum Genet118434443200510.1007/s00439-005-0073-116208513 LeeYHWitteTMomotTThe mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: Two case-control studies and a meta-analysisArthritis Rheum5239663974200510.1002/art.2148416320344 LeeYHRhoYHChoiSJJiJDSongGGAnkylosing spondylitis susceptibility loci defined by genome-search meta-analysisJ Hum Genet50453459200510.1007/s10038-005-0277-116175319 LeeYHRhoYHChoiSJJiJDSongGGMeta-analysis of genome-wide linkage studies for bone mineral densityJ Hum Genet51480486200610.1007/s10038-006-0390-916534542 XiaJFjellCDMayerMLPenaOMWishartDSHancockREINMEX - a web-based tool for integrative meta-analysis of expression dataNucleic Acids Res41W63W70201310.1093/nar/gkt338237662903692077 BarrettTTroupDBWilhiteSENCBI GEO: Archive for functional genomics data sets - 10 years onNucleic Acids Res39D1005D1010201110.1093/nar/gkq1184 AltmanRAschEBlochDDevelopment of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism AssociationArthritis Rheum2910391049198610.1002/art.17802908163741515 BolstadBMIrizarryRAAstrandMSpeedTPA comparison of normalization methods for high density oligonucleotide array data based on variance and biasBioinformatics19185193200310.1093/bioinformatics/19.2.18512538238 ChoiJKYuUKimSYooOJCombining multiple microarray studies and modeling interstudy variationBioinformatics19Suppl 1i84i90200310.1093/bioinformatics/btg101012855442 DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials7177188198610.1016/0197-2456(86)90046-23802833 FalconSGentlemanRUsing GOstats to test gene lists for GO term associationBioinformatics23257258200710.1093/bioinformatics/btl567 RamosYFBosSDLakenbergNGenes expressed in blood link osteoarthritis with apoptotic pathwaysAnn Rheum Dis7318441853201310.1136/annrheumdis-2013-20340523864235 LambertCDubucJEMontellEGene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membraneArthritis Rheumatol66960968201410.1002/art.38315247571474033569 Ruiz-VelascoVIkedaSRPuhlHLCloning, tissue distribution, and functional expression of the human G protein beta 4-subunitPhysiol Genomics84150200210.1152/physiolgenomics.00085.200111842130 KitagawaMLeeSHMcCormickFSkp2 suppresses p53-dependent apoptosis by inhibiting p300Mol Cell29217231200810.1016/j.molcel.2007.11.03618243116 BaiCSenPHofmannKSKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-boxCell86263274199610.1016/S0092-8674(00)80098-78706131 GanXWangJWangCPRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12Nat Cell Biol14686696201210.1038/ncb2507226099863389271 TriplettJWPavalkoFMDisruption of alpha-actinin-integrin interactions at focal adhesions renders osteoblasts susceptible to apoptosisAm J Physiol Cell Physiol291C909C921200610.1152/ajpcell.00113.200616807302 AyralXPickeringEHWoodworthTGMackillopNDougadosMSynovitis: A potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patientsOsteoarthritis Cartilage13361367200510.1016/j.joca.2005.01.00515882559 HillCLHunterDJNiuJSynovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritisAnn Rheum Dis6615991603200710.1136/ard.2006.067470174910962095318 RevellPAMaystonVLalorPMappPThe synovial membrane in osteoarthritis: A histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodiesAnn Rheum Dis47300307198810.1136/ard.47.4.30032591251003511 SakkasLIScanzelloCJohansonNT cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritisClin Diagn Lab Immunol54304371998966594495595 NakamuraHYoshinoSKatoTTsuruhaJNishiokaKT-cell mediated inflammatory pathway in osteoarthritisOsteoarthritis Cartilage7401402199910.1053/joca.1998.022410419780 JasinHEImmune mediated cartilage destructionScand J Rheumatol Suppl76111116198810.3109/030097488091029602908010 WangQRozelleALLepusCMIdentification of a central role for complement in osteoarthritisNat Med1716741679201110.1038/nm.2543220573463257059

Venn diagram showing the overlap between DE genes identified from the meta-analysis (Meta-DE) and those combined from the individual data analyses (individual-DE). DE, differentially expressed.

Summary of the enriched GO terms for the list of DE genes in patients with OA compared to controls. GO, gene ontology; DE, differentially expressed; OA, osteoarthritis.

Characteristics of the individual studies included in the meta-analysis.

Study (ref) GEO accession Patient number
Sample Platform
OA Control
1 (25) GSE48556 106 33 Blood Illumina HumanHT-12 V3.0 Expression Beadchip
2 (26) GSE46750 12 12 Synovial membrane Illumina HumanHT-12 V4.0 Expression Beadchip
3 (4) GSE32317 19 7 Synovial membrane Affymetrix Human Genome U133 Plus 2.0 Array

GEO, Gene Expression Omnibus; OA, osteoarthritis; ref, reference.

Top 20 upregulated and downregulated genes in patients with OA.

A, Top 20 upregulated genes
Entrez ID Gene symbol Combined ES P-value Gene name
6502 SKP2 −1.1447 5.36E-07 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase
23299 BICD2 −1.0632 4.24E-06 Bicaudal D homolog 2 (Drosophila)
8445 DYRK2 −0.8747 0.000592 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
10116 FEM1B −0.9170 0.000842 Fem-1 homolog b (C. elegans)
87 ACTN1 −0.8544 0.000842 Actinin, α 1
147906 DACT3 −0.8450 0.000867 Dishevelled-binding antagonist of β-catenin 3
6627 SNRPA1 −0.7981 0.002369 Small nuclear ribonucleoprotein polypeptide A'
84458 LCOR −0.7596 0.004996 Ligand dependent nuclear receptor corepressor
55670 PEX26 −0.7396 0.007656 Peroxisomal biogenesis factor 26
284273 ZADH2 −0.7241 0.009756 Zinc binding alcohol dehydrogenase domain containing 2
2983 GUCY1B3 −0.7239 0.009756 Guanylate cyclase 1, soluble, β 3
90550 MCU −0.7115 0.012319 Mitochondrial calcium uniporter
359845 FAM101B −0.7042 0.014203 Family with sequence similarity 101, member B
158381 ATP8B5P −0.7025 0.014203 ATPase, classI, type 8B, member 5, pseudogene
92014 MCART1 −0.7010 0.014203 Mitochondrial carrier triple repeat 1
57456 KIAA1143 −0.6989 0.014452 KIAA1143
51002 TPRKB −0.6918 0.015972 TP53RK binding protein
84953 MICALCL −0.9119 0.015993 MICAL C-terminal like
80071 CCDC15 −0.7894 0.018113 Coiled-coil domain containing 15
160 DAB2 −1.0979 0.049846 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)
B, Top 20 downregulated genes
Entrez ID Gene symbol Combined ES P-value Gene name
79899 PRR5L 1.3235 4.42E-09 Proline rich 5 like
5583 PRKCH 1.2343 5.08E-08 Protein kinase C, η
3683 ITGAL 1.2126 6.62E-08 Integrin, α L
5051 PAFAH2 1.0668 4.24E-06 Platelet-activating factor acetylhydrolase 2, 40kDa
24144 TFIP11 0.9820 4.31E-05 Tuftelin interacting protein 11
9595 CYTIP 0.9816 4.31E-05 Cytohesin 1 interacting protein
157567 ANKRD46 1.0119 7.59E-05 Ankyrin repeat domain 46
23294 ANKS1A 0.9547 7.60E-05 Ankyrin repeat and sterile α motif domain containing 1A
55272 IMP3 1.2776 0.001032 IMP3, U3 small nucleolar ribonucleoprotein
80213 TM2D3 1.0182 0.001425 TM2 domain containing 3
474344 GIMAP6 1.1551 0.004506 GTPase, IMAP family member 6
55303 GIMAP4 1.2787 0.008432 GTPase, IMAP family member 4
10866 HCP5 1.1647 0.001232 HLA complex P5 (non-protein coding)
54499 TMCO1 1.0355 0.014452 Transmembrane and coiled-coil domains 1
951 CD37 1.0423 0.023921 CD37 molecule
50650 ARHGEF3 1.0568 0.025483 ρ guanine nucleotide exchange factor (GEF) 3
56833 SLAMF8 1.0983 0.033534 SLAM family member 8
65992 DDRGK1 1.4283 0.033711 DDRGK domain containing 1
112858 TP53RK 1.7509 0.036334 TP53 regulating kinase
4236 MFAP1 1.2892 0.047164 Microfibrillar-associated protein 1

ES, effect size; OA, osteoarthritis.

Top 10 upregulated and downregulated genes in the synovial membrane of patients with OA.

A, Upregulated genes
Entrez ID Gene symbol Combined ES P-value Gene name
221895 JAZF1 −1.6865 0.004003 JAZF zinc finger 1
59345 GNB4 −1.6774 0.004003 Guanine nucleotide binding protein (G protein), β polypeptide 4
3070 HELLS −1.6193 0.005903 Helicase, lymphoid-specific
9749 PHACTR2 −1.5892 0.005903 Phosphatase and actin regulator 2
9645 MICAL2 −1.5726 0.006072 Microtubule associated monooxygenase, calponin and LIM domain containing 2
10974 C10orf116 −1.5715 0.006072 Adipogenesis regulatory factor
283310 OTOGL −1.5624 0.006072 Otogelin-like
26230 TIAM2 −1.5531 0.006563 T-cell lymphoma invasion and metastasis 2
51194 IPO11 −1.5378 0.006822 Importin 11
1404 HAPLN1 −1.5176 0.007348 Hyaluronan and proteoglycan link protein 1
B, Downregulated genes
Entrez ID Gene symbol Combined ES P-value Gene name
27242 TNFRF21 1.8378 0.003981 Tumor necrosis factor receptor superfamily, member 21
84225 ZMYND15 1.8026 0.003981 Zinc finger, MYND-type containing 15
9562 MINPP1 2.0472 0.004003 Multiple inositol-polyphosphate phosphatase 1
3600 IL15 1.9554 0.004003 Interleukin 15
3487 IGFBP4 1.7005 0.004003 Insulin-like growth factor binding protein 4
54504 CPVL 1.6845 0.004003 Carboxypeptidase, vitellogenic-like
9450 LY86 1.6796 0.004003 Lymphocyte antigen 86
147798 TMC4 1.6305 0.004882 Transmembrane channel-like 4
834 CASP1 1.5939 0.005903 Caspase 1, apoptosis-related cysteine peptidase
83401 ELOVL3 1.8314 0.006822 ELOVL fatty acid elongase 3

ES, effect size; OA, osteoarthritis.

Top 10 enriched GO terms among the DE genes in patients with OA compared with controls.

GO ID Term P-value Genes
GO:0006955 Immune response 0.000129438 ITGAL, GIMAP5, INPP5D, LAX1, GZMA, IRF1, CST7, SKAP1, CD55, TNFRSF4, CD37, CX3CR1, HLA-C, CXCL3
GO:0002252 Immune effector process 0.000288619 ITGAL, GIMAP5, INPP5D, IRF1, CD55, TNFRSF4, CD37, CX3CR1
GO:0002920 Regulation of humoral immune response 0.000308832 GIMAP5, CD55, CD37
GO:0042981 Regulation of apoptotic process 0.000510947 PRKCH, SKP2, PAFAH2, TMBIM6, GIMAP5; DYRK2, ACTN1, FEM1B, INPP5D, GZMA, IRF1, TNFRSF4, CX3CR1, ARHGEF3
GO:0051250 Negative regulation of lymphocyte activation 0.000517654 GIMAP5, INPP5D, LAX1, IRF1
GO:0045589 Regulation of regulatory T cell differentiation 0.000531439 GIMAP5, IRF1
GO:0043067 Regulation of programmed cell death 0.000551712 PRKCH, SKP2, PAFAH2, TMBIM6, GIMAP5, DYRK2, ACTN1, FEM1B, INPP5D, GZMA, IRF1, TNFRSF4, CX3CR1, ARHGEF3
GO:0050776 Regulation of immune response 0.000555143 PRKCH, ITGAL, GIMAP5, INPP5D, IRF1, SKAP1, CD55, CD37, HLA-C
GO:0002684 Positive regulation of immune system process 0.000593511 PRKCH, ITGAL, GIMAP5, INPP5D, IRF1, SKAP1, CD55, TNFRSF4, CD37
GO:0010941 Regulation of cell death 0.000708372 PRKCH, SKP2, PAFAH2, TMBIM6, GIMAP5, DYRK2, ACTN1, FEM1B, INPP5D, GZMA, IRF1, TNFRSF4, CX3CR1, ARHGEF3

GO, gene ontology; DE, differentially expressed; OA, osteoarthritis; ITGAL, Integrin, α L; GIMAP5, GTPase, IMAP family member 5; INPP5D, inositol polyphosphate-5-phosphatase; LAX1, lymphocyte transmembrane adaptor 1; GZMA, granzyme A; IRF1, interferon regulatory factor 1; SKAP1, src kinase associated phosphoprotein 1; TNFRSF4, tumor necrosis receptor superfamily, member 4; CX3CR1, CX3C chemokine receptor 1; HLA-C, humna leukocyte antigen C; CXCL3, chemokine (C-X-C motif) ligand 3; PRKCH, protein kinase C, η; SKP2, S-phase kinase-associated protein 2, E3 ubiquitin protein ligase; PAFAH2, platelet-activating factor acetylhydrolase 2, 40kDa; TMBIM6, transmembrane BAX inhibitor motif containing 6; DYRK2, Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2; ACTN1, Actinin, α 1; FEM1B, Fem-1 homolog b (C. elegans); ARHGEF3, ρ guanine nucleotide exchange factor (GEF) 3.